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With Biomaterials
Michael E. Davis, Patrick C.H. Hsieh, Alan J. Grodzinsky, Richard T. Lee
Abstract—Many strategies for repairing injured myocardium are under active investigation, with some early encouraging
results. These strategies include cell therapies, despite little evidence of long-term survival of exogenous cells, and gene
or protein therapies, often with incomplete control of locally-delivered dose of the factor. We propose that, ultimately,
successful repair and regeneration strategies will require quantitative control of the myocardial microenvironment. This
precision control can be engineered through designed biomaterials that provide quantitative adhesion, growth, or
migration signals. Quantitative timed release of factors can be regulated by chemical design to direct cellular
differentiation pathways such as angiogenesis and vascular maturation. Smart biomaterials respond to the local
environment, such as protease activity or mechanical forces, with controlled release or activation. Most of these new
biomaterials provide much greater flexibility for regenerating tissues ex vivo, but emerging technologies like
self-assembling nanofibers can now establish intramyocardial cellular microenvironments by injection. This may allow
percutaneous cardiac regeneration and repair approaches, or injectable-tissue engineering. Finally, materials can be
made to multifunction by providing sequential signals with custom design of differential release kinetics for individual
factors. Thus, new rationally-designed biomaterials no longer simply coexist with tissues, but can provide precision
bioactive control of the microenvironment that may be required for cardiac regeneration and repair. (Circ Res.
2005;97:8-15.)
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One of the ubiquitous facts of life in cell biology labora-tories is that cells are finicky about their growth condi-
tions. Cells grow best in certain media and on certain
substrates, and many cells require specific signals to prevent
differentiation, or other signals to guide differentiation. In
laboratory jargon, we say “these cells like this” or “those cells
need that.” This trivial observation that cells require highly
specific conditions has enormous implications for regenera-
tive medicine. For example, the majority of cells injected into
the myocardium won’t survive1; those cells that do survive
don’t necessarily couple physiologically with the native
myocardium.2,3 This is not surprising given the drastic change
in the local milieu of normal or injured myocardium com-
pared with the idealized conditions of the laboratory incuba-
tor. Thus, even if we get cells in the right places at the right
time, whether they live and develop into normally functioning
mature tissue will be determined by the local cellular
microenvironment.
Ultimately, regenerating tissues must have spatially and
temporally orchestrated distributions of growth factors. Some
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proteins like epidermal growth factor (EGF) can confine
signaling to short distances or even only to the cell that
secreted the EGF ligand, so control of EGF signaling on the
length scale of a single cell may be necessary.4 In contrast,
other factors like insulin-like growth factor-1 (IGF-1) may act
at great distances within a tissue or through the circulation.5
In addition, the local microenvironmental concentration of
factors is probably crucial. For example, many studies have
focused on injection of large quantities of vascular endothe-
lial growth factor (VEGF) protein or overexpression of
VEGF by gene transfer, but the precise VEGF microenviron-
mental concentration is a critical determinant of functional
vessel formation.6 Excessive VEGF can lead to abnormal
blood vessel formation, including irregular lumen formation,
leaky vessels, and hemangiomas.6
Thus, careful control of the cellular microenvironment may
be as important for achieving regeneration or repair as the
nature of the cells themselves. One of the critical ways that
we can control the local cellular microenvironment is through
biomaterials that are designed to direct cellular behavior. The
term, biomaterials, has many definitions, and one traditional
definition is that a biomaterial is a nonliving substance used
in a medical device, like a joint prosthesis. But the technology
of biomaterials has evolved, and the expanded definition
includes substances that are designed to control the biological
environment of cells and tissues. More than being simply
compatible with the host and serving a structural role,
biomaterials can now instruct cells through microenviron-
mental cues. Although most bioactive material strategies have
been designed for noncardiac tissues like bone, there are
many lessons from these studies that apply to future myocar-
dial applications.
Biomaterials for Cells
Many 3-dimensional materials are under investigation for
myocardial tissue engineering, including fibrin glue, poly
lactic-coglycolic acid (PLGA), self-assembling peptide nano-
fibers, gelatin hydrogels, and hyaluronic acid (HA) hydro-
gels.7–9 There are substantial challenges for existing materials
for implantation including poor vascularization, stimulation
of the host inflammatory response, and toxic degradation.10
Thus far, no material has promoted the myocardial cell
survival, maturation, and physiological integration necessary
for functional repair. Investigators have now turned to a
variety of chemical modifications of the local microenviron-
ment within these matrices.
Controlling Cellular Adhesion
Cellular adhesion was an undesirable property for traditional
biomaterials, because encapsulation and fibrosis were detri-
mental reactions. For myocardial tissues, however, promoting
endothelial adhesion and cardiomyocyte adhesion is obvi-
ously beneficial. One strategy is to incorporate the common
integrin adhesion peptide sequence RGD. Cannizzaro et al
used biotin-streptavidin linkages to bind biotin-RGD peptide
sequences to biotinylated poly(ethylene glycol) (PEG) and
poly-lactic acid copolymers.11 This resulted in increased
endothelial cell spreading in the polymer. Wang et al attached
RGD moieties to poly(ether urethane) (PEU) surfaces; this
modification greatly increased endothelial cell adhesion and
viability rates when compared with PEU alone.12 RGD
sequences are not cell-specific, however, and RGD peptides
bound to silicon membranes result in enhanced fibroblast
adhesion as well.13
Simple availability of cellular adhesion ligands is insuffi-
cient to maximize adhesion, because the spacing and orien-
tation of RGD ligands are also important. Lee et al varied the
nanoscale organization of RGD in alginate gel adhesion of
preosteoblasts.14 Regardless of the bulk density of RGD
islands, changing the spacing between the RGD islands
altered cell spreading and proliferation. In addition to RGD
peptide sequences, entire extracellular matrix proteins can be
coupled to biomaterials to promote endothelial cell adhesion
or to orient other adhesive proteins. For example, osteopontin
has an RGD sequence and promotes endothelial cell survival
and angiogenesis,15 but binding of osteopontin to a surface in
random orientations may limit its adhesive properties. Colla-
gen I can be used to bind osteopontin to polymers in
orientations that promote endothelial adhesion.16 Thus, both
spacing and orientation of adhesion sequences can regulate
cellular adhesion.
Controlling Biodegradation
Optimally, a myocardial biomaterial must degrade without
toxicity and with a controlled degradation rate. Unlike a
permanently implanted structural prosthesis, myocardial scaf-
folds should last long enough to guide integration of recruited
or applied cells, but not persist so long as to interfere with the
eventual cell–cell physiological coupling essential in the
myocardium. Various approaches can control biomaterial
degradation. Burdick et al studied the effect of hyaluronic
acid macromer concentration on the properties of photopoly-
merizable networks.17 Varying macromer concentration in-
creased degradation time by hyaluronidase from 1 day to
38 days. Accelerating degradation can compromise me-
chanical integrity of a biomaterial, and thus it is desirable to
control independently degradation and stiffness. Kong et al
showed that modifying alginates could preserve stiffness but
accelerate degradation, improving bone formation by bone
marrow stromal cells.18 Similarly, Lee et al demonstrated that
cross-linking of oxidized guluronate hydrogels could disso-
ciate degradation from mechanical stiffness.19 Thus, degra-
dation of polymers may potentially be designed for the
necessary regenerative strategy while at least temporarily
maintaining mechanical integrity.
Controlling Porosity
The pore size and pore connectivity of a bioactive material
are key factors. Pores on a length scale of microns to
millimeters influence trafficking of cells; myocardial cell
dimensions are typically 10 m to 100 m. Large inter-
connected pores can be beneficial for promoting colonization
of biomaterials,20 but excessively large pores could impair
vascularization, because endothelial cells are unable to bridge
pores greater than a cell diameter.21 Porosity can affect the
integrity of the material and thus cellular effects may need to
be balanced with mechanical properties.20,22,23 In contrast,
pores 100 nanometers will influence diffusion of nutrients
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and factors. Poor diffusion of oxygen and nutrients may cause
the failure of many implanted grafts and poor survival of
implanted cells.10 Diffusion in polymers is dependent on pore
size (both length and cross-sectional area) and pore num-
bers.24 Some hydrogels, like those formed by self-assembling
peptides (described below), have very small pore sizes that
promote endothelial adhesion and capillary formation, but
still allow rapid migration of cells because the hydrogels are
very flexible.25
Protein Delivery
Although many biomaterials can provide necessary mechan-
ical support and adhesion sites, they cannot guide cellular
phenotype as growth factors can. Superficially, binding
growth factors to various biomaterials for delivery may
appear to be a relatively simple task. However, the design of
protein delivery systems must meet several criteria that are
specific to the protein and the application.26 The delivered
factor should not only be beneficial in the biological process,
but increasing the amount of that factor over the endogenous
level must have an additional beneficial effect. Delivery of a
protein to receptors that are already optimally activated by the
endogenous protein in fact may be detrimental, as described
for overexpression of VEGF.6,27–29 In addition, the factor
should be targeted to the specific population of cells to reduce
the possibility of toxic effects on other cells. Finally, the
kinetics of release, degradation, and spatial distribution are
critical. For example, a chemotactic factor must be delivered
with the gradient that drives chemotaxis, but the gradient
should dissipate when the recruited cells are present. Thus,
the strategy for protein delivery must be highly tailored.
Many materials implanted into mammals will adsorb large
quantities of proteins nonspecifically, a process called foul-
ing, and known to stimulate the foreign body reaction.8 It is
important for permanent implants to be nonfouling to mini-
mize giant cell formation and encapsulation. In contrast,
biomaterials designed to deliver proteins and foster cell
growth use protein binding sites for delivery (Figure 1). Some
proteins such as platelet-derived growth factor and fibroblast
growth factor-2 have domains that bind extracellular matrix
proteins or highly charged materials and limit diffusion,30,31
whereas other proteins like IGF-1 diffuse more rapidly.
Kanematsu et al incorporated a variety of different growth
factors into collagenous matrices32 and found very different
release profiles from the matrices both in vitro and in vivo,
with rapid loss of IGF-1 compared with other factors. These
data reinforce that growth factor release must be designed
specifically for the target indication.
In addition to covalently coupling factors and nonspecific
binding to biomaterials, delivery of factors can be achieved
through the unusually high affinity of streptavidin for biotin.
Because this molecular Velcro interaction is very high affin-
ity, and because streptavidin is a tetramer with 4 binding sites
for biotin, biotinylated polymers can be easily coupled to
factors via streptavidin.33 As mentioned above, Cannizzaro et
al used this technique to link RGD to PLA-PEG polymers.11
Additionally, Hoya et al found that fluorophore-conjugated
avidin delivered via tail vein injection bound specifically to
the kidney microvasculature surfaces that were biotinylated.34
This demonstrates the potential for delivering a factor to a
biotinylated material in vivo. Release of biotin-streptavidin
bound factors is expected to be very slow, but biofunctional
streptavidin polymer constructs can be engineered to allow
release of biotin-coupled factors.35
Delivery of Angiogenic Factors
In myocardial tissue, each myocyte is immediately adjacent
to several capillaries. The diffusion of oxygen alone dictates
that any successful attempt to regenerate myocardium will be
dependent on the proper spatial vascularization.36,37 Endothe-
lial cells also provide growth and survival signals to cardiac
myocytes, and endothelial cells may promote electrical cou-
pling of myocytes.38 Adverse ventricular remodeling may be
prevented, at least in part, by neovascularization of the
infarcted area.39 Therefore, promoting myocardial angiogen-
esis may have an impact beyond the obvious benefit of
oxygen and blood supply. Although clinical trials of myocar-
dial therapeutic angiogenesis have largely been disappointing
to date,40 this may be caused by inadequate controls on dose
and control of delivery.41 Biomaterial-based angiogenic pro-
tein delivery offers promise for better control of local
therapeutic angiogenesis.
Most studies of angiogenic protein factors in biomaterial
delivery have evaluated single factors like FGF-2 and VEGF.
For example, Iwakura et al incorporated FGF-2 into gelatin
hydrogels and injected hydrogel microspheres directly into
rat myocardium 4 weeks after infarction.42 Injection of the
Figure 1. Protein release by biomaterials. There are several
potential mechanisms for protein delivery by biomaterials. (1)
Tethered growth factor incorporation. A modification is made to
either the polymer or the factor to tether the factor to the bio-
material. (2) The growth factor is incorporated within micro-
spheres or noncovalently coupled to the material to allow quan-
titative control of release. (3) Proteolytic “smart” release, when
the factor is tethered by an enzymatically-cleaveable sequence
allowing release only when that protease is present and active.
(4) The future of protein delivery by biomaterials is a multifunc-
tional, bioactive material consisting of combinations of delivery
methods.
10 Circulation Research July 8, 2005
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gelatin microspheres increased myocardial perfusion and new
vessel formation at the center of the infarct as well as the
border zones. Both regional and global systolic function
improved after 4 weeks of treatment. This strategy has had
preliminary clinical success in patients undergoing coronary
bypass surgery.43 When sustained-release heparin-alginate
microcapsules with FGF-2 were surgically implanted in
ischemic and viable but ungraftable myocardium, there was a
trend toward improved perfusion and no apparent adverse
effects. FGF-2 in the serum of patients who received myo-
cardial controlled-release FGF-2 was not increased. VEGF
can also be delivered by hydrogels, and some data suggest
that this is a particularly effective approach for delivering
VEGF.44
Because angiogenesis arises from a series of events that
include recruitment of cells but must also include further
maturation of the new vessels,45 biomaterials are an attractive
means of providing multiple signals. Marui et al loaded a
combination of FGF-2 and hepatocyte growth factor into
collagen microspheres.46 The single growth factors were not
able to improve blood flow as measured by laser Doppler
imaging; however, the dual growth factor approach resulted
in an increase in blood flow, as well as increased vessel
formation and maturity. Richardson et al used polymer
microspheres to encapsulate VEGF and PDGF and examined
angiogenesis after hind-limb ischemia induction.47 The au-
thors were able to vary the release rates of the growth factors
by incorporating 1 factor into the polymer directly and the
other embedded in microspheres within the polymer. Protein
release profiles were determined by changing the degradation
rates by altering polymer formulations. When implanted
subcutaneously after hind-limb ischemia, the dual growth
factor approach improved angiogenesis and increased vessel
size and maturity compared with the individual factors alone.
Thus, temporally controlled, multiple factor release by bio-
materials is a promising approach to therapeutic
angiogenesis.
Smart Biomaterials Respond to
Their Environment
One of the most challenging problems in tissue engineering
and regeneration is to reproduce the serial signals that
comprise normal developmental processes and successful
regeneration in nature. In relatively few circumstances will
we aim to deliver several factors with identical kinetics.
Therefore, the future of bioactive materials is in design of
smart biomaterials that respond to their environment with
predetermined responses such as protein release, allowing not
only delayed release but release initiated by microenviron-
mental conditions.48 Although the design of smart biomate-
rials is in its infancy, the potential for engineering these
materials has been demonstrated by recent studies. Various
disease conditions can lead to increases in local temperature,
acidity, or metalloproteinase activation, and these microenvi-
ronment conditions can be exploited by smart biomaterials
(Figure 2).
Metalloproteinase-Mediated Release
Matrix metalloproteinases (MMPs) can cleave a variety of
substrates including components of the extracellular matrix.
MMP activation is easily demonstrated in remodeling myo-
cardium, and both pharmacological and gene deletion studies
have demonstrated a role for MMPs in progressive cardiac
dilation.49 Because MMPs recognize specific amino acid
sequences, act locally in the pericellular environment, and are
normally expressed at low levels in quiescent tissues, MMPs
are potential triggers for smart biomaterial behavior. Chau et
al designed dextran-methotrexate conjugates for potential
tumor therapy, fast growing tumors express high levels of
MMP-2 and MMP-9.50 The methotrexate was attached to
dextran via a peptide that contained a cleavage sequence for
MMP-2 and MMP-9. This led to a time-dependent release of
methotrexate in vitro by MMP-2 or MMP-9. Furthermore,
methotrexate was released by conditioned media from tumor
cells that express MMP-2 and MMP-9, but not from tumor
cells that did not express these enzymes. The sequence
specificity of the peptide was demonstrated by poor release
profiles when scrambled peptide linkers or no peptide linkers
were used to couple the methotrexate. MMP-sensitive link-
ages could thus be used to release factors in response to tissue
remodeling enzymes. Similarly, Lutolf et al developed hy-
drogels with MMP-sensitive linkages between polyethylene
glycol chains entrapping bone morphogenetic protein-2.51
This strategy allowed rapid bone formation in rats because of
proteolytic invasiveness of the gels and subsequent release of
bone morphogenetic protein-2. Thus, there is potential to use
this smart biomaterial approach to deliver factors to the
myocardium in response to MMPs stimulated by cardiac
remodeling.
In addition to enzymatic recognition sequences, proteins
can be released from biomaterials by pH changes. Many
biomaterials are internalized by cells via endocytosis. In the
acidic endosome, a biomaterial can be designed to destroy the
endosome and release the factor to the cytoplasm. Murthy et
al created a polymer with a membrane-disruptive backbone
attached to polyethylene glycol via acid-sensitive linkers.52
Drugs and recognition sequences were tethered and then
released in hepatocyte endosomes.
Another example of smart biomaterials is the release of
proteins in response to mechanical forces, which is highly
relevant to the myocardium. Mechanical stimuli induce ex-
pression of the VEGF gene and protein in a variety of cells,53
including cardiac myocytes. Lee et al developed an analogous
biomaterial approach with VEGF-containing alginate hydro-
gels. When these hydrogels were exposed to mechanical
strain in vitro, the release rate of VEGF increased. After
implantation in ischemic hind-limbs of diabetic mice, this
mechanically-induced release also increased collateral vessel
formation.54 Thus, biomaterials could potentially be designed
to respond to mechanical loads to help regenerating myocytes




One of the most important barriers to cardiac tissue engineer-
ing is that any new tissue must engraft into the already-
diseased myocardium with electrophysiological and mechan-
ical integration. This challenge is daunting for integrating
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large volume of myocardial tissue, which must also appro-
priately vascularize, but could be addressed by reconstitution
of small microenvironments of myocardium in situ. Small
microenvironments could conceivably be introduced by in-
jection percutaneously, in the same manner that some cell
therapies are currently performed. The concept of injectable
tissue engineering has been most vigorously pursued to date
in the orthopedic arena.55 However, recent progress in mo-
lecular self assembly suggests that in situ cardiac reconstitu-
tion may be possible with new biomaterials.
Building new myocardium with injectable microenviron-
ments may be accomplished with emerging nanotechnology
approaches. Nanotechnology refers broadly to manipulation
and design on the molecular level, generally 1 to 100
nanometers. Nanofibers (7 to 20 nanometers in diameter)
can be designed to self-assemble under a variety of conditions
with specific peptides. Molecular self-assembly occurs natu-
rally (eg in protein folding) and is mediated by weak
noncovalent interaction between molecules via hydrogen
bonding, van der Waals interactions, ionic bonds, and hydro-
phobic interactions.56 Nature has created a wide variety of
molecules that are amphiphilic, having both hydrophilic and
hydrophobic regions. Amphiphilic molecules like phospho-
lipids can undergo self-assembly and can be designed to form
nanotubes and nanospheres. Amphiphilic peptide sequences
can also be designed with alternating hydrophobic and
hydrophilic amino acids, and these peptides are in solution at
low pH or low osmolarity. However, when exposed to
physiological ionic strength and pH conditions, the peptides
interact and self-assemble into stable nanofibers that inter-
weave rapidly to form a hydrated gel.56
Although hydrogels from self-assembling peptides don’t
contain typical integrin-binding motifs, they can be outstand-
ing cell culture substrates and 3-D encapsulation culture
systems. Chondrocytes cultured within peptide nanofiber
hydrogels produce a cartilage-like extracellular matrix rich in
glycosaminoglycans and collagen, and the progressive accu-
mulation of matrix leads to cartilage-like mechanical behav-
ior.57 Liver progenitor cells embedded within peptide nano-
fibers adopt mature hepatocyte properties including
Figure 2. Smart biomaterials react to the local environment. A, An acid-sensitive linker is used to tether a growth factor to a membrane
disruptive compound. At neutral pH, the complex is stable; however when the complex enters an endosome and is exposed to acidic
pH, the linker is dissolved, leaving the membrane disruptor to destroy the endosome and releasing the factor into the cell.52 B, Bioma-
terials can respond to the mechanical conditions of the tissue. The release of the factor is controlled by the compression of the tis-
sue.54 C, Biomaterials can be designed to release factors in the presence of matrix metalloproteinases. In disease states where specific
MMPs are secreted and activated, the linker customized to contain specific recognition sequences allows protease-mediated release.51
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binucleation and expression of cytochrome P450s that sug-
gest hepatocyte maturation.58 Endothelial cells cultured
within nanofiber scaffolds form typical capillary-like net-
works in vitro. Interestingly, coculture of cardiac myocytes
with endothelial cells leads to rapid assembly of capillary-like
channels, with accumulation of cardiac myocytes on the
outside of the endothelial-lined channel. The endothelial cells
promote connexin 43 expression and electrical synchrony of
the cardiac myocytes.38 This suggests that endothelial cells
and cardiac myocytes retain the ability to assemble into
myocardium-like structures, and that injection of cells in the
appropriate self-assembling peptides could allow cells to
assemble in situ.
The biophysical properties of self-assembling peptides are
well-suited to building myocardial microenvironments by
injection, because they can be maintained in solution but form
nanofibers at normal pH and osmolarity. When injected into
the left ventricular free wall of mice, the nanofibers create
hydrogel microenvironments easily discernable by standard
histology (Figure 3). Initially, the nanofibers are cell-free, but
they are then spontaneously populated by endothelial cells,
with clear capillary structures forming over a period of
weeks.59 Over time, the vascular structures express matura-
tion markers such as -smooth muscle actin, and the vascular
structures contain red blood cells, suggesting coupling to the
host vasculature.
Self-assembling peptide nanofibers can be modified in a
broad variety of manners, allowing cell-specific signals to be
delivered. For example, Silva et al synthesized self-
assembling peptides containing an IKVAV epitope.60 This
sequence is found in laminin and encourages neurite adhesion
and growth. When cultured within these microenvironments,
neuron progenitors differentiated into neurons. Further mod-
ifications of peptide sequences and design of smart peptide
nanofibers will allow controlled quantitative delivery of
factors to the myocardium.
Self-assembling peptide microenvironments can support
the growth and differentiation of embryonic stem cells to
cardiac myocytes within the myocardium.59 Because differ-
entiation of embryonic stem cells and other stem and progen-
itor cells is highly dependent on local microenvironmental
factors, the ability to modify bioactive injectable materials
like peptide nanofibers may be a crucial component of future
cell therapy strategies. For example, long-term, the clinical
use of embryonic stem cells would be prohibited by even rare
formation of teratomas. Delivery of local factors that ensure
differentiation of all of the stem cells in the microenviron-
ment could be a key crucial factor in preventing the devel-
opment of teratomas.
Although many types of bioactive biomaterials have been
developed, relatively few have been used to modify the
hostile environment of infarcted myocardium. These include
fibrin glue and alginate preparations, with early suggestions
of improvement in neovascularization and cardiac remodel-
ing.7 Preliminary studies suggest that self-assembling peptide
nanofiber microenvironments are stable within infarcted
myocardium and can be engineered to deliver myocardial
survival factors efficiently (unpublished observations).
Biomaterials for Gene Delivery
Although many problems have delayed gene transfer ap-
proaches as viable therapies, critical issues such as toxicity
and quantitative control of delivery may be addressed by new
biomaterials. Naked DNA injection into the heart fails be-
cause of low transfection efficiencies, nonspecific targeting to
multiple cell types, and degradation. Current viral methods
for widespread myocardial delivery do not appear clinically
viable. Implantation of transfected cells to deliver proteins
has interesting potential but this type of genetically-
engineered cell therapy will be limited by survival of im-
planted cells as well as control over the amount of protein
secreted. Thus, there is a potential role for the development of
biomaterials that quantitatively delivery DNA to target cells
or to enhance survival of gene-targeted cells. Polymers can
protect DNA from degradation, allowing persistent transfec-
tion by endocytosis for months.61 Although very few attempts
have been made to deliver DNA to the myocardium, there has
been some limited success. Christman et al mixed fibrin glue,
a biopolymer formed by mixing fibrinogen with thrombin,
with DNA encoding the gene for the angiogenic protein
pleitropin. Injection of the DNA within fibrin glue into
ischemic rat myocardium led to increased neovasculature
formation as compared with fibrin glue or plasmid injection
alone.62 Although biomaterials may help solve some prob-
lems facing myocardial gene therapy like degradation of
DNA and survival of transfected cells, the quantitative
problems of gene control make protein delivery by biomate-
rials a more attractive approach.
Conclusions
The unprecedented excitement over molecular and cell ap-
proaches to cardiac repair should be tempered by the com-
Figure 3. Self-assembling peptide nanofibers create injectable
myocardial micronenvironments. Mouse myocardium was
injected with self-assembling peptide nanofibers. The nanofibers
assemble into a local microenvironment in vivo (dotted lines)
that is easily distinguishable from the native myocardium (NM)
under standard light microscopy. This microenvironment con-
tains many nuclei (blueDAPI) at this stage (14 days). The
microenvironment contains endothelial cells (greenisolectin;
these cells also stain for CD31) that cluster (arrows) and eventu-
ally form functional vessels.59 In addition, cells that stain posi-
tively for myocyte markers (red-sarcomeric actin) are also
present and tend to be located adjacent or nearby endothelial
cells (circles show these cells located near endothelial cells).
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plexity of the regeneration response. Regeneration requires a
precise series of spatially and temporally controlled events
analogous to the remarkably coordinated events of organ
development. Although our initial single factor or single
cell-type approaches may yield benefit, it is likely that we
will have to design multi-factorial strategies for cardiac
repair. For this reason, new biomaterials that provide cell
instructions in precisely controlled manners may be essential.
Advances in bioactive biomaterials allow not only controlled
release, but protection of factors from degradation or release
of factors in response to environmental cues. The design of
these new biomaterials will require substantial fundamental
biological insight, because factors such as dose, timing,
spatial range of delivery, and the conditions for
environmentally-controlled release will be highly specific for
the target tissue and disease. Ultimately, though, novel
biomaterials may be used to guide the tissue repair response
at the pericellular level in the same manner that we guide cells
in the laboratory.
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